Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver General Hospital, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada.
J Mol Neurosci. 2011 Nov;45(3):402-8. doi: 10.1007/s12031-011-9551-1. Epub 2011 May 21.
Most cases of frontotemporal lobar degeneration (FTLD) are characterized by the abnormal accumulation of either the microtubule-associated protein tau or the transactive response DNA-binding protein with M(r) 43 kDa, TDP-43 (FTLD-tau and FTLD-TDP, respectively). However, there remain ∼10% of cases, composed of a heterogenous collection of uncommon disorders, for which the molecular basis remains uncertain. In this review, we describe the characteristic genetic, clinical, and pathological features of the major tau/TDP-negative FTLD subtypes, with focus on recent advances in our understanding of their molecular basis. This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.
大多数额颞叶变性(FTLD)病例的特征是微管相关蛋白 tau 或 43kDa 转导反应 DNA 结合蛋白,TDP-43(分别为 FTLD-tau 和 FTLD-TDP)的异常积累。然而,仍有约 10%的病例由一组不同的罕见疾病组成,其分子基础尚不确定。在这篇综述中,我们描述了主要的 tau/TDP-阴性 FTLD 亚型的特征性遗传、临床和病理特征,重点介绍了我们对其分子基础的理解的最新进展。这包括发现含有泛素化内含物的非典型 FTLD、神经元中间丝包涵体病和嗜碱性包涵体病的病理变化对融合肉瘤(FUS)蛋白呈免疫反应性,从而创建了一个新的分子亚组(FTLD-FUS),以及阐明致病性 CHMP2B 突变的功能后果的研究。